Abstract 1087
Background
Several lines of evidence suggest that the gut microbiome represents a novel biomarker in the era of immuno-oncology. Therefore, the prospective collection of fecal samples is now routinely included in clinical trials and acts as a new challenge for research nurses. However, little is known about patient compliance in the collection process. The objective of this study was to assess enrolment and compliance rates for fecal sample collection.
Methods
Fecal samples were prospectively collected in two academic institutions, University of Montreal Hospital and Gustave Roussy Cancer Center, using the International Human Microbiome Standards SOP Version 3 in the following groups: (1) patients with advanced non-small cell lung cancer (NSCLC) amenable to immune checkpoint inhibitors and (2) patients with early-stage NSCLC or renal cell carcinoma (RCC) at a pre-operative stage. Informed and written consent were obtained by research nurses and patient baseline characteristics were collected. Upon consent, a white opaque polypropylene pot with an anaerobic generator bag was provided to the patient, along with a document to explain the self-collection technique. Enrolment (signing of consent) and compliance (returning the sample) rates were analysed using a Chi-squared method.
Results
A total of 267 patients were eligible for the study and 252 (94%) patients with a median age of 64 agreed to sign the consent form. The enrolment rate in the study reached 96% (175/183) in patients receiving immunotherapy compared to 92% (77/84) in patients with early stage cancers undergoing surgical resection who did not receive immunotherapy (p = 0.01). Overall patient compliance was 81% (204/252). Importantly, compliance was significantly higher in the pre-immunotherapy setting (94%, 164/175) versus the pre-operative group (52%, 40/77) (p = 0.01). Furthermore, regardless of the cancer stage, women (82% or 77 patients) were more compliant than men (80% or 127 patients) (p = 0.02).
Conclusions
New tools to increase compliance and assist patients in sample collection should be developed, especially for male patients diagnosed with early stage disease who are undergoing surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bertrand Routy.
Funding
Montreal Cancer Institute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4600 - Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Presenter: Lucio Ghiglione
Session: Poster Display session 3
Resources:
Abstract
3547 - Real World Outcomes of Immune-Related Adverse Events (irAEs) among Patients Receiving Immune Checkpoint Inhibitors (ICIs) in Hospital Settings
Presenter: Saby George
Session: Poster Display session 3
Resources:
Abstract
1124 - Sex-based heterogeneity of efficacy of anticancer immunotherapy
Presenter: Fabio Conforti
Session: Poster Display session 3
Resources:
Abstract
4133 - Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis
Presenter: Qingyuan Huang
Session: Poster Display session 3
Resources:
Abstract
2548 - Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients
Presenter: Jacobo Rogado
Session: Poster Display session 3
Resources:
Abstract
2228 - Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma
Presenter: Antoine Italiano
Session: Poster Display session 3
Resources:
Abstract
2333 - Efficacy and safety of immune checkpoint inhibitors (ICIs) for treatment of advanced solid tumours in octogenarian patients
Presenter: Soraya Mebarki
Session: Poster Display session 3
Resources:
Abstract
4847 - Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies
Presenter: Aracelis Torres
Session: Poster Display session 3
Resources:
Abstract
2215 - Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting
Presenter: Pauline Corbaux
Session: Poster Display session 3
Resources:
Abstract
2881 - Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Joaquin Mosquera Martinez
Session: Poster Display session 3
Resources:
Abstract